Tech Company Financing Transactions
EpilepsyGTx Funding Round
UCL Technology Fund and HTH VC participated in a $10 million Seed funding round for EpilepsyGTx. The round was recorded on 6/24/2024.
Transaction Overview
Company Name
Announced On
6/24/2024
Transaction Type
Venture Equity
Amount
$10,000,000
Round
Seed
Investors
UCL Technology Fund (Lead Investor)
Proceeds Purpose
The company intends to use the funds to complete the preclinical studies for its lead gene therapy program EPY201, and to prepare a first-in-human, Phase 1/2a clinical study with EPY201 in focal refractory epilepsy.
Company Information
Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
Building 1000 Cambridge Research Park Beach Drive
Waterbeach Cambridgeshire, CB25 9PD
UK
Waterbeach Cambridgeshire, CB25 9PD
UK
Phone
Website
Email Address
Overview
EpilepsyGTx is a late preclinical-stage biotech developing cutting-edge gene therapies that will transform the management of focal refractory epilepsy (FRE). Focal epilepsy describes a group of disorders in which patients experience seizures that arise from a specific part of the brain1. Refractory epilepsy occurs when seizures persist despite trials of at least two tolerated and appropriately chosen antiseizure medicines2.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Nicolas Koebel
Chief Scientific Officer
Dimitri Kullmann
VP - R & D
Luiz Silva
Browse more venture capital transactions:
Prev: 6/24/2024: SoSoValue venture capital transaction
Next: 6/24/2024: TrackLight venture capital transaction
Share this article
About Database of VC Transactions
We do our best to report on tech company VC transactions. VC investment data records reported here are derived from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs